schizophrenia

News and resources

Month: September 2024

Sep 05 2024

Researchers discover a mechanism that impairs synaptic plasticity in the brains of schizophrenia patients – Medical Xpress

by Clinical Editor

No Comments

Researchers discover a mechanism that impairs synaptic plasticity in the brains of schizophrenia patients Medical Xpress

Sep 05 2024

Researchers discover a mechanism that impairs synaptic plasticity in the brains of schizophrenia patients

by Clinical Editor

No Comments

A study led by researchers at Tampere University has mapped genes linked to schizophrenia and uncovered a mechanism that disrupts synaptic plasticity in affected individuals. The researchers showed …

Sep 04 2024

Postpartum Psychosis as a Precursor to Schizophrenia: A Comprehensive Review – Cureus

by Clinical Editor

No Comments

Postpartum Psychosis as a Precursor to Schizophrenia: A Comprehensive Review Cureus

Sep 04 2024

How Do Women Deal With Schizophrenia & What Are The Symptoms, Signs & Challenges

by Clinical Editor

No Comments

Women with schizophrenia are much more hostile and face challenges that may cause them to act in the most unsuitable manner.

Sep 03 2024

Neurocrine reports mixed results on schizophrenia therapy in mid-stage trial – STAT

by Clinical Editor

No Comments

Neurocrine reports mixed results on schizophrenia therapy in mid-stage trial STAT

Sep 03 2024

Nxera wins $35m after Phase II schizophrenia trial success

by Clinical Editor

No Comments

Nxera will receive $35m from Neurocrine due to the successful completion of the Phase II trial of NBI-568 in schizophrenia.

Sep 02 2024

What Are the Different Types of Schizophrenia?

by Clinical Editor

No Comments

The five types of schizophrenia include catatonic, disorganized, residual, paranoid, and undifferentiated schizophrenia. Each has different symptoms.

Sep 02 2024

Neurocrine’s KarXT rival hits in phase 2 schizophrenia trial—but only at lowest dose

by Clinical Editor

No Comments

Neurocrine Biosciences has achieved its hoped-for profile in a phase 2 schizophrenia trial, delivering its targeted level of efficacy with a lower rate of gastrointestinal adverse events than Bristol Myers...